Chevy Chase, MD, 2 December 2024 – Uncommon Cures®, a pioneering organization dedicated to accelerating the development of orphan drugs, has announced a strategic collaboration with TASK, a leading global clinical research organization specializing in various therapeutic areas. This collaboration will combine Uncommon Cures’ innovative approaches to orphan drug development with TASK’s extensive clinical trial expertise, particularly across Europe and South Africa.
Under this partnership, Uncommon Cures and TASK will work together to streamline clinical trial processes, ensuring a faster and more efficient path to regulatory approval for orphan drugs. The collaboration aims to reduce the barriers associated with rare disease drug development, facilitating access to essential treatments for underserved patient populations.
“Our mission at Uncommon Cures is to eliminate obstacles in the clinical development of orphan drugs, making life-saving treatments more accessible for rare disease patients,” said Rob Freishtat, MD, MPH, President at Uncommon Cures. “Partnering with TASK, which shares our commitment to medical innovation and patient advocacy, strengthens our capacity to conduct robust clinical trials across diverse geographic regions. Together, we’re well-positioned to advance groundbreaking therapies that bring hope to patients who have limited options.”
TASK, with its clinical trial infrastructure spanning Europe and South Africa, has a proven track record in executing complex clinical studies for novel therapies. By integrating TASK’s specialized research capabilities, Uncommon Cures aims to expedite its drug development timelines, enhancing the potential for successful trial outcomes and rapid regulatory submission.
"Joining forces with Uncommon Cures allows TASK to play a crucial role in bringing much-needed orphan drugs to the global market,” said Johann de Bruyn, CA(SA), MBA, CEO at TASK. “Our shared goal is to streamline the clinical trial process, leverage our combined expertise, and address unmet medical needs. This partnership represents a significant step forward for patients, researchers, and the rare disease community."
As part of this collaboration, Uncommon Cures and TASK will engage with key stakeholders, including regulatory bodies and patient advocacy groups, to ensure that trial designs are patient-centered and aligned with global standards for safety and efficacy.
This partnership marks a significant milestone in Uncommon Cures' mission to transform the clinical development landscape for orphan drugs and is poised to make a profound impact on the lives of those affected by rare diseases worldwide.
For more information, please contact:
Rob Freishtat, President, Uncommon Cures
Phone: +1 240 338 1217; Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Jolize Gerber, Business Development Executive, TASK
Phone: +27 21 100 3606; Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
About Uncommon Cures®: Uncommon Cures is dedicated to expediting the development of orphan drugs through innovative clinical trial design, streamlined processes, and strategic partnerships. The organization’s mission is to make life-saving treatments more accessible to underserved patient populations worldwide.
About TASK: TASK is an internationally recognized clinical research organization dedicated to advancing healthcare through innovative and ethical clinical trials. TASK’s experienced scientists, clinicians, and regulatory experts deliver high-quality clinical research solutions. With state-of-the-art clinical trial facilities in Europe and South Africa, TASK is committed to improving health outcomes through rigorous scientific investigation.